Adderall Shortages Affecting ADHD Patients

Widespread shortages of Adderall and other versions of the drug used to treat attention deficit hyperactivity disorder (ADHD) are worsening in the United States, causing despair among patients who rely on the drug for to concentrate.

The largest U.S. maker of Adderall, Teva Pharmaceuticals Industries Ltd., said last month that a labor shortage earlier this year disrupted production, the Wall Street Journal reported. .

Pharmacists, manufacturers and patients are reporting shortages of ADHD medication Adderall nationwide. (Photo by Jb Reed/Bloomberg via Getty Images/Getty Images)

Teleprinter Security Last To change To change %
SUITS YOU TEVA PHARMACEUTICAL INDUSTRIES LTD. 8.46 -0.20 -2.37%

A Teva spokesperson said at the time that the company expects shortages at the retail level to be resolved in the coming weeks, but pharmacies are now reporting ADHD treatment shortages at home. a range of other drug manufacturers.

The American Society of Health-System Pharmacists (ASHP) reported shortages of several versions of the amphetamine from numerous manufacturers this week, as reports mount nationwide of the impact low supplies are having on patients unable to fill their prescriptions.

UNITEDHEALTH COMPLETES CHANGE HEALTH CARE MERGER AFTER COURT REJECTS DOJ CHALLENGE

“It scares people,” Dr. Robert Shulman, a psychiatrist at Rush University Medical Center, told FOX 32 in Chicago. “It scares parents who have kids starting school right now. It scares adults who rely on medication to get them through the workday. Patients can’t get their medications and we get a lot of calls phone calls, so it’s a lot of extra work, and patients have to call pharmacies to see where there’s a supply.”

Shulman says several factors are contributing to the shortages, including record high prescriptions for the drug following COVID-19 lockdowns, an increase in recreational use of the stimulant and manufacturing limits put in place by the federal government.

A spokesperson for Sandoz, a Novartis company that makes a generic version of Adderall, told FOX Business on Friday that there is no shortage of their product in the market and that the company “meets all current customer orders,” but pointed to regulatory factors that could be contributing to the situation with the drug.

BIOGEN SHARES RISE ON ALZHEIMER’S DRUG DEVELOPMENTS

The spokesperson explained that Sandoz, like other drugmakers, plans manufacturing based on customer pre-orders and is authorized to meet the level of ordering provided by the United States Drug Enforcement Administration. If a customer orders more than the drug manufacturers anticipate due to increased demand, the manufacturers are unable to fulfill those orders and they are considered “out of stock”.

Novartis

The Novartis AG Institutes for BioMedical Research building in Cambridge, Massachusetts (Photographer: Scott Eisen/Bloomberg via Getty Images/Getty Images)

Teleprinter Security Last To change To change %
NVS NOVARTIS AG 75.65 -0.39 -0.51%

Pharmaceutical companies must ask the DEA for an increase in production volume in this case. Some requests are accepted, others are refused. The DEA did not immediately respond to FOX Business’ request for comment on whether the agency recently raised the manufacturing limits of Adderall or plans to do so.

GET FOX BUSINESS ON THE ROAD BY CLICKING HERE

When contacted by FOX Business for comment, a U.S. Food and Drug Administration spokesperson did not confirm any Adderall-like drug shortages, but said in a statement that the agency “continues to monitor the supply of ADHD medications and [is] communicating with manufacturers regarding sourcing.”

Add Comment